tiprankstipranks
Vir Biotechnology, Inc. (MX:VIR)
NASDAQ:VIR
Mexico Market
VIR
Vir Biotechnology
RESEARCH TOOLSreports

Vir Biotechnology (VIR) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

VIR Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Vir
Biotechnology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$375.19
Based on 9 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $375.19 with a high forecast of $525.27 and a low forecast of $280.14. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"151":"$151","526":"$526","244.75":"$244.8","338.5":"$338.5","432.25":"$432.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":525.2652591,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$525.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":375.18947078571426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$375.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":280.14147152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$280.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[151,244.75,338.5,432.25,526],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.71,189.67578916153846,217.6415783230769,245.6073674846154,273.57315664615385,301.5389458076923,329.50473496923075,357.4705241307692,385.43631329230766,413.4021024538461,441.36789161538456,469.3336807769231,497.29946993846147,{"y":525.2652591,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.71,178.13149775274726,194.5529955054945,210.97449325824175,227.395991010989,243.81748876373626,260.2389865164835,276.6604842692308,293.081982021978,309.5034797747253,325.9249775274725,342.34647528021975,358.767973032967,{"y":375.18947078571426,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,161.71,170.82011319384617,179.9302263876923,189.04033958153846,198.15045277538462,207.26056596923075,216.37067916307691,225.48079235692308,234.5909055507692,243.70101874461537,252.81113193846153,261.92124513230766,271.03135832615385,{"y":280.14147152,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.71,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$525.27Average Price Target$375.19Lowest Price Target$280.14
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on MX:VIR
Michael Ulz
Morgan Stanley
Morgan Stanley
$402.7→$472.74
Buy
―
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Sutro Biopharma (NASDAQ: STRO) and Ardent Health Partners, Inc. (NYSE: ARDT)
H.C. Wainwright Analyst forecast on MX:VIR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$350.18
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Vir Biotechnology (NASDAQ: VIR)
Barclays Analyst forecast on MX:VIR
Etzer Darout
Barclays
Barclays
$525.27
Buy
―
Reiterated
06/01/26
Barclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)
Bank of America Securities Analyst forecast on MX:VIR
Alec Stranahan
Bank of America Securities
Bank of America Securities
$280.14
Buy
―
Reiterated
05/29/26
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
Leerink Partners Analyst forecast on MX:VIR
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
Needham Analyst forecast on MX:VIR
Joseph Stringer
Needham
Needham
$315.16
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)
Evercore ISI Analyst forecast on MX:VIR
Cory Kasimov
Evercore ISI
Evercore ISI
$315.16
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Gilead Sciences (NASDAQ: GILD) and Sera Prognostics (NASDAQ: SERA)
TD Cowen Analyst forecast on MX:VIR
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
Goldman Sachs Analyst forecast on MX:VIR
Paul Choi
Goldman Sachs
Goldman Sachs
$367.69
Buy
―
Reiterated
05/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)
Raymond James Analyst forecast on MX:VIR
Sean McCutcheon
Raymond James
Raymond James
$210.11→$332.67
Buy
―
Reiterated
02/24/26
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond JamesVir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on MX:VIR
Michael Ulz
Morgan Stanley
Morgan Stanley
$402.7→$472.74
Buy
―
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Sutro Biopharma (NASDAQ: STRO) and Ardent Health Partners, Inc. (NYSE: ARDT)
H.C. Wainwright Analyst forecast on MX:VIR
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$350.18
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA) and Vir Biotechnology (NASDAQ: VIR)
Barclays Analyst forecast on MX:VIR
Etzer Darout
Barclays
Barclays
$525.27
Buy
―
Reiterated
06/01/26
Barclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)
Bank of America Securities Analyst forecast on MX:VIR
Alec Stranahan
Bank of America Securities
Bank of America Securities
$280.14
Buy
―
Reiterated
05/29/26
Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target
Leerink Partners Analyst forecast on MX:VIR
Roanna Ruiz
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), GeoVax Labs (NASDAQ: GOVX) and Vir Biotechnology (NASDAQ: VIR)
Needham Analyst forecast on MX:VIR
Joseph Stringer
Needham
Needham
$315.16
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Revvity (NYSE: RVTY), Vir Biotechnology (NASDAQ: VIR) and Johnson & Johnson (NYSE: JNJ)
Evercore ISI Analyst forecast on MX:VIR
Cory Kasimov
Evercore ISI
Evercore ISI
$315.16
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), Gilead Sciences (NASDAQ: GILD) and Sera Prognostics (NASDAQ: SERA)
TD Cowen Analyst forecast on MX:VIR
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Vir Biotechnology Earns Buy Rating on Advancing Oncology and Hepatitis Delta Pipelines and Strong Cash Runway Into 2028
Goldman Sachs Analyst forecast on MX:VIR
Paul Choi
Goldman Sachs
Goldman Sachs
$367.69
Buy
―
Reiterated
05/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)
Raymond James Analyst forecast on MX:VIR
Sean McCutcheon
Raymond James
Raymond James
$210.11→$332.67
Buy
―
Reiterated
02/24/26
Vir Biotechnology upgraded to Strong Buy from Outperform at Raymond JamesVir Biotechnology upgraded to Strong Buy from Outperform at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
ENOVEnovis
GKOSGlaukos
IFRXInflaRx
BKDBrookdale Senior Living
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

3 Months
Phil NadeauTD Cowen
Success Rate
10/17 ratings generated profit
59%
Average Return
+8.42%
Copying Phil Nadeau's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +8.42% per trade.
1 Year
Phil NadeauTD Cowen
Success Rate
11/17 ratings generated profit
65%
Average Return
+33.28%
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +33.28% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
11/16 ratings generated profit
69%
Average Return
+27.48%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +27.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
16
14
15
17
14
Buy
2
1
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
15
17
19
16
In the current month, VIR has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 375.19.
Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is $5.83 with a range of -$15.23 to $25.39. The previous quarter’s EPS was -$14.88. VIR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.
Next quarter’s earnings estimate for VIR is $5.83 with a range of -$15.23 to $25.39. The previous quarter’s EPS was -$14.88. VIR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $2.38B with a range of $14.01M to $4.66B. The previous quarter’s sales results were -$507.76K. VIR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.
Next quarter’s sales forecast for VIR is $2.38B with a range of $14.01M to $4.66B. The previous quarter’s sales results were -$507.76K. VIR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Stock Forecast FAQ

What is MX:VIR’s average 12-month price target, according to analysts?
Based on analyst ratings, Vir Biotechnology, Inc.’s 12-month average price target is 375.19.
    What is MX:VIR’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:VIR, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Vir Biotechnology, Inc. a Buy, Sell or Hold?
        Vir Biotechnology, Inc. has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Vir Biotechnology, Inc.’s share price target?
          The average share price target for Vir Biotechnology, Inc. is 375.19. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $525.27 ,and the lowest forecast is $280.14. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Vir Biotechnology, Inc.?
            Vir Biotechnology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
              How can I buy shares of Vir Biotechnology, Inc.?
              To buy shares of MX:VIR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.